Granted Patent
B2
US 7,345,041 · App. 11/334,267 · Granted Mar 18, 2008
Chemical compounds
Assignee:
SmithKline Beecham Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to methods for the treatment of a sleep disorder comprising administering a compound of formula (I): wherein all variables are as defined herein.
Claims (3)
1. A method for the treatment of a sleep disorder in a mammal in need thereof, said method comprising administering an effective amount of 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide methanesulphonate.
2. The method of claim 1 wherein said mammal is man.
3. The method of claim 1 wherein said sleep disorder is selected from dysomnia, insomnia, sleep and circadian rhythmic disorder.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 13, 2012
From: GLAXOSMITHKLINE LLC
To: GLAXO GROUP LIMITED
Reel/Frame 027692/0320 →
CHANGE OF NAME
Recorded Jan 25, 2012
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 027588/0500 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 22, 2007
From: GLAXO GROUP LIMITED
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 019051/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 19, 2007
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXO GROUP LIMITED
Reel/Frame 018898/0671 →
Priority Claims (1)
GB 9923748.9
· Oct 7, 1999
· national
Continuity (4)
Continuation
1008996400